Glyburide, gliclazide or glimepiride in the elderly with type 2 diabetes: a review of the clinical effectiveness and safety
Canadian Agency for Drugs and Technologies in Health
Record ID 32011001020
English
Authors' recommendations:
There was no evidence identified concerning the clinical effectiveness of glyburide when compared to gliclazide or glimepiride for elderly patients with type 2 diabetes. The evidence available concerning the safety of glyburide, gliclazide or glimepiride is limited and inconclusive. In one study there is some suggestion that glyburide may be associated with a greater risk of all-cause mortality compared to gliclazide.
Details
Project Status:
Completed
URL for project:
http://www.cadth.ca/media/pdf//htis/june-2011/RC0285_Glyb_Glic_Glim_for_Eld_with_T2DM_Final.pdf
Year Published:
2011
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Aged
- Diabetes Mellitus, Type 2
- Gliclazide
- Glyburide
- Sulfonylurea Compounds
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.